Paper Session II-B - Strategies for Conducting Life Science Experiments Beyond Low Earth Orbit

Human exploration beyond low Earth orbit will require terrestrial life to survive and ultimately flourish in environments fundamentally different to those in which it has evolved. The effects of deep space and conditions on the surface of other planets must be studied to understand and reduce the risks to explorers, provide bioregenerative life support, and make full use of the broad research opportunities and scientific benefits offered by such unique environments. Though much is already known about biological adaptations to the space environment, key changes in terrestrial life may only be revealed over complete life cycles and across multiple generations living beyond Earth. The demands and potential risks of exploring and inhabiting other worlds necessitate a detailed understanding of these changes at all levels of biological organization, from genetic alterations to impacts on critical elements of reproduction, development, and aging. Results from experiments conducted beyond low Earth orbit will contribute to the safety of space exploration and address fundamental questions of life\u27s potential beyond its planet of origin. Research campaigns will include a combination of core studies and innovative, Pl-driven investigations. Multiple flight platforms-including free flyers and planetary bases-may support a range of manned and unmanned mission opportunities

Protein and calorie intakes in adult and pediatric subjects with urea cycle disorders participating in clinical trials of glycerol phenylbutyrate

Background: Little prospectively collected data are available comparing the dietary intake of urea cycle disorder (UCD) patients to UCD treatment guidelines or to healthy individuals. Objective: To examine the protein and calorie intakes of UCD subjects who participated in clinical trials of glycerol phenylbutyrate (GPB) and compare these data to published UCD dietary guidelines and nutritional surveys. Design: Dietary data were recorded for 45 adult and 49 pediatric UCD subjects in metabolic control during participation in clinical trials of GPB. Protein and calorie intakes were compared to UCD treatment guidelines, average nutrient intakes of a healthy US population based on the National Health and Nutrition Examination Survey (NHANES) and Recommended Daily Allowances (RDA). Results: In adults, mean protein intake was higher than UCD recommendations but lower than RDA and NHANES values, while calorie intake was lower than UCD recommendations, RDA and NHANES. In pediatric subjects, prescribed protein intake was higher than UCD guidelines, similar to RDA, and lower than NHANES data for all age groups, while calorie intake was at the lower end of the recommended UCD range and close to RDA and NHANES data. In pediatric subjects height, weight, and body mass index (BMI) Z-scores were within normal range (−2 to 2). Conclusions: Pediatric patients treated with phenylbutyrate derivatives exhibited normal height and weight. Protein and calorie intakes in adult and pediatric UCD subjects differed from UCD dietary guidelines, suggesting that these guidelines may need to be reconsidered